# Narration and storyboard draft: Semaglutide Microdosing and Clinical Outcomes

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Semaglutide has strong clinical evidence at the doses actually tested. The popular microdosing claim asks a narrower question: does weekly maintenance strictly below 0.5 milligrams produce sustained, meaningful weight loss? Our review examined 59 relevant original reports, including three selected Methods and Results checks. It found no randomized trial matching that exact dose, placebo comparison and 24-to-68-week horizon. The early low weekly dose study lasted only 12 weeks. A positive low-milligram obesity trial used daily injections, so it cannot be converted into a weekly trial by arithmetic. Real-world tailoring reports mix doses, select people already doing well or add other treatments. Food-noise reduction is reported by patients, but retrospective recall does not show that it is necessary for weight loss. Muscle mass is also different from strength: some studies show grip improvement despite lean loss, while others raise concerns in older adults. The HSEF grade is Gamma, mechanistically plausible with partial system support. That is an evidence gap, not proof of no effect. A direct, controlled maintenance-dose trial with weight, harms and function measured together would answer the question.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.